We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Five Prime Therapeutics, Inc. announced today to have entered into a two year collaborative research and license agreement with Boehringer Ingelheim to discover novel therapeutic products to treat rheumatoid arthritis and other diseases.
The drug maker Novartis said Monday that first-quarter profit rose 31 percent from the year-earlier period, helped by demand for the hypertension treatment Diovan and a gain from the sale of its nutrition unit.
Pharmaceutical manufacturer Plethico, headquartered in India, plans to construct a new, $20 million manufacturing facility in Kenya, the company reported.
Doxapram, a central nervous system stimulant, has been shown to help speed recovery from sevoflurane anesthesia, a type of inhaled anesthetic, according to a study published in the Canadian Journal of Anesthesiology.
UK-based Astex Therapeutics has reported that the U.S. FDA has approved its investigational new drug (IND) application for the clinical development of its proprietary aurora kinase inhibitor, AT9283, for the treatment of cancer.
The U.S. FDA has approved Japanese drugmaker Astellas Pharma's Prograf a drug that suppresses the body's immune response for the prevention of graft rejection in heart transplant recipients.
Taro Pharmaceuticals Industries Inc. (TARO) said Monday it received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for carvedilol tablets and for ondansetron hydrochloride tablets.
UCB (Nachrichten) announces that it has reached an agreement with Recordati (Nachrichten) to transfer back the sales and marketing rights in Germany of Corifeo, an antihypertensive calcium channel blocker, for a payment to UCB of 10 million euros.